Literature DB >> 12621478

Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival.

A Gustafsson Jernberg1, M Remberger, O Ringdén, J Winiarski.   

Abstract

To examine whether graft-versus-host-disease (GVHD) is associated with a graft-versus-leukaemia (GVL) effect that also influences the outcome of allogeneic stem cell transplantation (SCT) in childhood acute leukaemia, we evaluated all consecutive (n=169) children who had undergone SCT for ALL and AML at our centre. Median follow-up was 7 years. The 5-year probability of chronic GVHD was 34%. Median time to relapse was 24 months in children with chronic GVHD and 6 months in those without. The corresponding 5-year probabilities of relapse were 30 and 45% (P=0.01). The 5-year probability of survival was 54%. Patients with chronic GVHD had a significantly better survival, 77 vs 51% (P=0.01). In a Cox regression model, chronic GVHD independently decreased the risk of relapse (RR 0.44) and further predicted an increased chance of relapse-free survival (RR 1.7) and survival (RR 2.6). The impact of chronic GVHD on survival was most apparent in late-stage disease and in ALL. Acute GVHD was not an independent predictor for relapse or death in this study. This study is in support of a GVL effect in childhood leukaemia related to chronic GVHD, reducing the risk of relapse and improving survival.

Entities:  

Mesh:

Year:  2003        PMID: 12621478     DOI: 10.1038/sj.bmt.1703808

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

1.  The devil is in the T cells: relapsing after haploidentical hematopoietic cell transplantation.

Authors:  M Byrne; B N Savani
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

Review 2.  Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.

Authors:  Christianne Bourlon; Dennis Lacayo-Leñero; Sergio I Inclán-Alarcón; Roberta Demichelis-Gómez
Journal:  Curr Oncol Rep       Date:  2018-03-26       Impact factor: 5.075

3.  Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?

Authors:  M A Pulsipher; B Langholz; D A Wall; K R Schultz; N Bunin; W Carroll; E Raetz; S Gardner; R K Goyal; J Gastier-Foster; M Borowitz; D Teachey; S A Grupp
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

4.  Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission.

Authors:  Kristin M Page; Myriam Labopin; Annalisa Ruggeri; Gerard Michel; Cristina Diaz de Heredia; Tracey O'Brien; Alessandra Picardi; Mouhab Ayas; Henrique Bittencourt; Ajay J Vora; Jesse Troy; Carmen Bonfim; Fernanda Volt; Eliane Gluckman; Peter Bader; Joanne Kurtzberg; Vanderson Rocha
Journal:  Biol Blood Marrow Transplant       Date:  2017-04-21       Impact factor: 5.742

Review 5.  New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.

Authors:  M A Pulsipher; A S Wayne; K R Schultz
Journal:  Bone Marrow Transplant       Date:  2014-06-16       Impact factor: 5.483

6.  The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.

Authors:  Byung-Sik Cho; Yoo-Jin Kim; Seok-Goo Cho; Sung-Yong Kim; Ki-Seong Eom; Hee-Je Kim; Seok Lee; Chang-Ki Min; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2007-06       Impact factor: 2.490

7.  The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.

Authors:  Michael A Pulsipher; Bryan Langholz; Donna A Wall; Kirk R Schultz; Nancy Bunin; William L Carroll; Elizabeth Raetz; Sharon Gardner; Julie M Gastier-Foster; Denise Howrie; Rakesh K Goyal; James G Douglas; Michael Borowitz; Yvonne Barnes; David T Teachey; Candace Taylor; Stephan A Grupp
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

Review 8.  Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.

Authors:  P Tsirigotis; M Byrne; C Schmid; F Baron; F Ciceri; J Esteve; N C Gorin; S Giebel; M Mohty; B N Savani; A Nagler
Journal:  Bone Marrow Transplant       Date:  2016-06-13       Impact factor: 5.483

9.  Unrelated hematopoietic stem cell transplantation in the pediatric population: single institution experience.

Authors:  Daniela Hespanha Marinho; José Zanis Neto; Carmem Maria Sales Bonfim; Vaneuza Araujo Moreira Funke; Lisandro Lima Ribeiro
Journal:  Rev Bras Hematol Hemoter       Date:  2015-06-03

10.  Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation.

Authors:  Shabnam Shokouhi; Sarah Bray; Salar Bakhtiyari; Kourosh Sayehmiri; Kamran Alimoghadam; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.